The University of Iowa Selects TrialX to Build SAYSTOP Study App for a Leading Research Study to Investigate Antibiotics Resistance
Summary
Brett Faine, PharmD, MS, of the Department of Emergency Medicine, at the University of Iowa and David Talan, MD of the Department of Emergency Medicine at the University of California, Los Angeles are investigating if it is safe for patients to stop their antibiotics when they feel better compared to completing all their antibiotic pills for urinary tract infections (UTI). The University of Iowa and University of California, Los Angeles selected TrialX to develop a user-friendly mobile application tailored for remote data collection for this clinical study.During the study, participants will receive medications that will come in two separate blister packs for the treatment of their UTI, from which they will make a switch during the study, while tracking symptoms and antibiotic intake. "We believe that technology plays a pivotal role in addressing challenges related to clinical trials and the SAYSTOP Study App is a testament to that belief," said Brett Faine, the co-principal investigator, and “Through this collaboration with TrialX, we hope to gather valuable insights into antibiotic usage patterns and ultimately develop strategies to mitigate the spread of antibiotic resistance. By harnessing the power of decentralized clinical trial technology, we aim to empower clinical research investigators to simplify and accelerate their study data collection to discover useful insights that guide future strategies in healthcare.The SAYSTOP Study App is available for download on both iOS and Android devices. TrialX products include an award-winning patient recruitment management platform), a remote research data collection (ePRO/eCOA) platform and an online talk show, all designed to facilitate collection, analysis, and dissemination of clinical research data across web, mobile or stand-alone devices.